HIGH-DOSE RATE BRACHYTHERAPY IN PATIENTS WITH LOCAL RECURRENCES AFTER RADIOTHERAPY OF NON-SMALL-CELL LUNG-CANCER

被引:48
|
作者
SUTEDJA, G [1 ]
BARIS, G [1 ]
SCHAAKEKONING, C [1 ]
VANZANDWIJK, N [1 ]
机构
[1] NETHERLANDS CANC INST,DEPT RADIOTHERAPY,1066 CX AMSTERDAM,NETHERLANDS
关键词
BRACHYTHERAPY; NON-SMALL-CELL LUNG CANCER; RECURRENCES;
D O I
10.1016/0360-3016(92)91072-U
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thirty-one patients with recurrences of locally advanced Stage III lung cancer were treated with high dose rate brachytherapy. All patients had previously received a full course external beam irradiation. All treatments were performed under topical anaesthesia and took 6-14 min depending on the strength of the Iridium-192 source. The high dose rate brachytherapy was calculated as 10 Gy at one cm from the source axis for each session and this was repeated every 2 weeks to a maximum of three sessions. All treatments were well tolerated and no immediate treatment related complications were observed. Response evaluation 6 weeks after high dose rate brachytherapy showed that there was a partial response in 22 patients and nine patients were non-responders. Median survival was 7 and 3 months, respectively. All non-responders had initially presented with a T4N3 tumor. Ten patients died because of fatal pulmonary hemorrhages 2-24 weeks after brachytherapy and three others died because of a bronchial fistula. Endobronchial brachytherapy appears to be a valuable treatment alternative for local palliation. However, the relatively high number of complications at follow-up warrants further investigation to establish the optimal benefit to be derived from high dose rate brachytherapy treatment of locally advanced Stage III tumors.
引用
收藏
页码:551 / 553
页数:3
相关论文
共 50 条
  • [31] HIGH-DOSE CYTARABINE IN SMALL-CELL LUNG-CANCER
    OSBORNE, RJ
    CLARK, PI
    SLEVIN, ML
    WRIGLEY, PFM
    CANCER TREATMENT REPORTS, 1987, 71 (04): : 417 - 418
  • [32] Nodal recurrences after stereotactic body radiotherapy for early stage non-small-cell lung cancer
    Tibdewal, Anil
    Pathak, Rima S.
    Agarwal, Jai Prakash
    Hoskote, Sumedh S.
    Mummudi, Naveen
    Iyer, Veena
    Nair, Akshay G.
    CURRENT PROBLEMS IN CANCER, 2021, 45 (02)
  • [33] LOCAL AND/OR DISTANT RECURRENCES IN T1-2/NO-1 NON-SMALL-CELL LUNG-CANCER
    CANGEMI, V
    VOLPINO, P
    DANDREA, N
    PUOPOLO, M
    FABRIZI, S
    LONARDO, MT
    PIAT, G
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1995, 9 (09) : 473 - 478
  • [34] CLINICAL STAGING OF PATIENTS WITH NON-SMALL-CELL LUNG-CANCER
    LITTLE, AG
    STITIK, FP
    CHEST, 1990, 97 (06) : 1431 - 1438
  • [35] Palliative radiotherapy for non-small-cell lung cancer: Which dose?
    Hoskin, PJ
    CLINICAL ONCOLOGY, 2005, 17 (01) : 59 - 60
  • [36] Carcinomatous Meningitis in Non-Small-Cell Lung Cancer: Response to High-Dose Erlotinib
    Dhruva, Nirav
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) : E31 - E32
  • [37] High-dose radiotherapy for the treatment of inoperable non-small cell lung cancer
    Sura, Sonal
    Yorke, Ellen
    Jackson, Andrew
    Rosenzweig, Kenneth E.
    CANCER JOURNAL, 2007, 13 (04): : 238 - 242
  • [38] High-dose hyperfractionated accelerated radiotherapy in non-small cell lung cancer
    De Ruysscher, D.
    Reymen, B.
    Van Baardwijk, A.
    MINERVA CHIRURGICA, 2011, 66 (04) : 341 - 345
  • [39] A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer - An EORTC lung cancer cooperative group trial
    Planting, A
    Helle, P
    Drings, P
    Dalesio, O
    Kirkpatrick, A
    McVie, G
    Giaccone, G
    ANNALS OF ONCOLOGY, 1996, 7 (02) : 139 - 144
  • [40] CHEMOTHERAPY IN NON-SMALL-CELL LUNG-CANCER
    THATCHER, N
    RANSON, M
    LEE, SM
    NIVEN, R
    ANDERSON, H
    ANNALS OF ONCOLOGY, 1995, 6 : 83 - 95